Publisher： John Wiley & Sons Inc
E-ISSN： 1365-2990|44|1|6-17
ISSN： 0305-1846
Source： NEUROPATHOLOGY & APPLIED NEUROBIOLOGY, Vol.44, Iss.1, 2018-02, pp. : 6-17
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Over the last decade, there has been increasing evidence that hyperactivation of the mechanistic target of rapamycin (mTOR) pathway is a hallmark of malformations of cortical development such as focal cortical dysplasia (FCD) or hemimegalencephaly. The mTOR pathway governs protein and lipid synthesis, cell growth and proliferation as well as metabolism and autophagy. The molecular genetic aetiology of mTOR hyperactivation has only been recently clarified. This article will review the current and still evolving genetic advances in the elucidation of the molecular basis of FCD. Activating somatic mutations in the MTOR gene are to date the most frequent mutations found in FCD brain specimens.
Related content
Access to resources
Recommend
mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia
EPILEPSIA, Vol. 56, Iss. 4, 2015-04 ,pp. :
Somatic Mutations in the MTOR gene cause focal cortical dysplasia type IIb
ANNALS OF NEUROLOGY, Vol. 78, Iss. 3, 2015-09 ,pp. :
Familial focal epilepsy with focal cortical dysplasia due to DEPDC5 mutations
ANNALS OF NEUROLOGY, Vol. 77, Iss. 4, 2015-04 ,pp. :